Top M&A advisors in Boston, MA ranked by AI search visibility. Bain Capital ($185B), TA Associates HQ'd here. TrustRank scored by ProCloser.ai. Q1 2026.
We evaluated 158 m&a advisors serving Boston and ranked the top 8 by TrustRank — our composite score of AI search visibility, verified client reviews, and content authority.
Boston is a significant M&A market, anchored by Bain Capital, TA Associates, Advent International. Deal multiples average 9.4× EBITDA for middle-market transactions.
Boston generates roughly 200+ M&A transactions annually, with 9.4× EBITDA multiples and total deal value exceeding $140B+. Approximately 68% of deals involve private equity sponsors. The local PE ecosystem includes Bain Capital, TA Associates, Advent International, giving sellers in the region access to a competitive buyer pool. Massachusetts's tax environment (5% flat + 4% surtax on income >$1.05M = 9% top rate) influences deal structuring, particularly for founder-owned business exits.
Key local M&A networks include ACG Boston and CFA Society Boston — 6,000+ members; NE's largest (est. 1946). Dealmakers should note that Massachusetts's tax environment (5% flat + 4% surtax on income >$1.05M = 9% top rate) directly impacts deal structure and seller net proceeds.
Our independent scoring system for m&a advisors in Boston
TrustRank is not a paid placement. We independently evaluated 158 m&a advisors serving Boston across three measurable dimensions. No firm can pay to appear or improve its rank.
We tracked 50 prompts across ChatGPT, Perplexity, Google AI Overviews, and Claude asking about m&a advisors in Boston. The % of prompts where each firm appears.
Aggregate ratings across Google, Clutch, and the ProCloser.ai verified review system. Weighted by volume and recency of verified client reviews.
Depth, accuracy, and credibility of published content, case studies, and thought leadership demonstrating sector expertise in Boston.
The world's leading M&A advisory firm with a dominant presence in Boston, known for complex middle-market and upper-middle-market transactions across all sectors.
Premier middle-market M&A advisory firm with experienced dealmakers in Boston specializing in founder-owned business exits and PE-backed transactions.
Global middle-market investment bank with deep relationships in Boston's private equity community, consistently delivering strong outcomes for sell-side mandates.
Long-tenured investment bank with a strong Boston presence offering buy-side and sell-side advisory, equity research, and capital markets services to growth companies.
Full-service investment bank with sector-focused M&A teams serving Boston businesses in financial services, healthcare, and consumer sectors.
Boutique M&A advisory firm specializing in lower-middle-market transactions for Boston business owners in technology, government services, and healthcare sectors.
One of the most active M&A advisory firms in the lower-middle-market, with dedicated Boston advisors who have helped hundreds of regional business owners exit successfully.
Global M&A firm with strong Boston deal flow, connecting local sellers with international buyers and providing full-service transaction advisory from valuation to close.
Boston is the dominant US market for life sciences M&A, with Kendall Square functioning as the global epicenter of biotech acquisitions. Strategic buyers like Pfizer, AstraZeneca, and Merck maintain permanent deal teams in Cambridge. The city's M&A market also covers deep-tech, defense, and enterprise software, though pharma exits dwarf all other verticals.
Massachusetts has a robust state AG review process for healthcare M&A under Chapter 176I, requiring 60-day advance notice for material changes in healthcare operations. Biotech deals involving federally-funded IP may require NIH review. FINRA CRD requirements apply to registered advisors. The MA Division of Professional Licensure oversees broker-dealer activity at the state level.
Biotech M&A fees in Boston frequently include milestone triggers — a base success fee that scales upward if the deal includes contingent value rights (CVRs) tied to FDA approval stages, adding significant complexity to advisor compensation negotiations.
Common questions about choosing m&a advisors in Boston, MA.
Reviewed by: Tania Kozar — ProCloser.ai Research | Last Updated: April 2026 | Sources: SEC IAPD, FINRA BrokerCheck, state regulatory filings, ProCloser.ai primary research.
Related Rankings
If you're a m&a advisors serving Boston and want to improve your AI search visibility, ProCloser.ai can help you appear when prospects ask ChatGPT, Perplexity, and Google AI Overviews for recommendations.
